Cite
Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study.
MLA
Huang, J., et al. “Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: A Prospective, Single-Arm and Multicentre Study.” Clinical Oncology, vol. 36, no. 1, Jan. 2024, pp. 39–45. EBSCOhost, https://doi.org/10.1016/j.clon.2023.11.030.
APA
Huang, J., Zhang, X.-H., Cai, Y., Yang, D., Shi, J., Xing, P., Xu, T., Wu, L., Su, W., Xu, R., Wei, T., Chen, H.-J., & Yang, J.-J. (2024). Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study. Clinical Oncology, 36(1), 39–45. https://doi.org/10.1016/j.clon.2023.11.030
Chicago
Huang, J., X.-H. Zhang, Y. Cai, D. Yang, J. Shi, P. Xing, T. Xu, et al. 2024. “Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: A Prospective, Single-Arm and Multicentre Study.” Clinical Oncology 36 (1): 39–45. doi:10.1016/j.clon.2023.11.030.